Answer
Imatinib potently inhibits Bcr-Abl tyrosine kinase and selectively inhibits proliferation and induces apoptosis in Bcr-Abl-positive cell lines and fresh leukaemic cells from patients with Philadelphia chromosome-positive CML or acute lymphoblastic leukaemia.
Sources for this answer
- GLIVEC film-coated tabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 41Document updated
Sources checked